Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erenumab + sumatriptan
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (erenumab), Subcutaneous, Oral, Intranasal (sumatriptan)
01
Overview
**erenumab + sumatriptan** is a combination of two agents used in the management of migraine. **Erenumab** is a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor (CGRP receptor), acting as a CGRP receptor antagonist, which is used for the prevention of migraine. **Sumatriptan** is a serotonin 5-HT1B/1D receptor agonist (triptan class), used for the acute treatment of migraine by inducing cranial vasoconstriction and inhibiting the release of vasoactive neuropeptides. The combination addresses both migraine prevention (erenumab) and acute treatment (sumatriptan). Clinical pharmacology studies show that co-administration does not result in significant pharmacodynamic or pharmacokinetic interactions and is well tolerated[1][3][4][5].
- Brand names
- Aimovig (erenumab)Imitrex (sumatriptan)others for sumatriptan
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on erenumab + sumatriptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erenumab + sumatriptan.